The emerging role of ACE inhibitors in diabetes: From theory to therapeutic management

Journal of Diabetes and its Complications

Volumn 10, Issue 3, 1996, Pages 129-132

  Yudkin, John S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; INSULIN RESISTANCE; MICROALBUMINURIA; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030152930     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(96)00034-7     Document Type: Conference Paper

References (40)

1. Jarrett RJ, Viberti GC, Argyropoulos A, et al: Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabetic Med 1:17-19, 1984.
2. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984.
3. Messent JWC, Elliott TG, Hill RGD, Jarrett J, Keen H, Viberti G: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int 41:836-839, 1992.
4. Borch-Johnsen K, Kreiner S: Proteinuria: Vaoue as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 294:1651-1654, 1987.
5. Yudkin JS, Forest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet ii: 530-533, 1988.
6. Yudkin JS: Microalbuminuria in non-diabetic individuals: a prognostic index of cardiovascular disease, in: Andreucci VE, Fine LG (eds), International Yearbook of Nephrology Dialysis Transplantation. Oxford, Oxford University Press, pp. 59-74.
7. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC: Plasma lipid and coagulation factor concentrations in insulin-dependent diabetics with microalbuminuria. BMJ 298:487-490, 1989.
8. Jay RH, Jones SL, Hill CE, Richmond W, Viberti GC, Rampling MW, Betteridge DJ: Blood rheology and cardiovascular risk factors in type I diabetes: Relationship with microalbuminuria. Diabetic Med 8:662-667, 1991.
9. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Voutilainen E, Pentilla I, Pyorala K: Microalbuminuria predicts the development of serum lipoprotein abnormalities favoring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33:237-243.
10. Kapelrud H, Bangstad H-J, Dahl-Jørgensen K, Berg K, Hanssen KF: Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. BMJ 303:675-768, 1991.
11. Mathiesen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T: Incipient nephropathy in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 26:406-410, 1984.
12. Haffner SM, Stern MP, Gruber MKK, Hazuda HP, Mitchell BD, Patterson JK: Microalbuminuria. Potential marker for increased cardiovascular risk factors in non-diabetic subjects? Arteriosclerosis 10:727-731, 1990.
13. Pinkney JH, Mohamed-Ali V, Denver AE, Foster C, Sampson MJ, Yudkin JS: Insulin resistance, insulin, proinsulin, and ambulatory blood pressure in type II diabetes. Hypertension 24:362-367, 1994.
14. Hansen KW, Mau Pedersen M, Marshall SM, Christiansen JS, Mogensen CE: Circadian variation of blood pressure in patients with diabetic nephropathy. Diabetologia 35:1074-1079, 1992.
15. Sampson MJ, Chambers J, Sprigings D, Drury PL: Intraventricular septal hypertrophy in Type 1 diabetic patients with microalbuminuria or early proteinuria. Diabetic Med 7:126-131, 1990.
16. Nosadini R, Cipollina MR, Solini A, Sambataro M, Morocutti A, Doria A, Fioretto P, Brocco E, Muollo B, Frigato F: Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin-dependent diabetes mellitus. J Am Soc Nephrol 3:S56-S63, 1992.
17. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G: Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883-886, 1993.
18. Pinkney JH, Yudkin JS: Microalbuminuria is associated with insulin resistance in subjects with Type II diabetes. Diabetologia 1996 (in press).
19. Feldt-Rasmussen B: Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 29:282-286, 1986.
20. Stehouwer CDA, Nauta JJP, Zendenrust GC, Hackeng WHL, Denker AJM, Den Ottolander GJH: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319-323, 1992.
21. Baron AD: Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone. Baillieres Clin Endocrinol Metab 7:961-987, 1993.
22. Yudkin JS: Effects of ACE inhibition on cardiovascular risk factors, insulin resistance and microalbuminuria. Clin Cardiol 1996 (in press).
23. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 17:448-454, 1987.
24. Fernere M, Lachkar H, Richard J-L, Bringer J, Orsetti A, Mirouze J: Captopril and insulin sensitivity. Ann Intern Med 102:134-135, 1985.
25. Torlone E, Rambotti AM, Perriello G, Botta G, Santeusanio F, Brunetti P, Bolli GB: ACE inhibition increased hepatic and extrachepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 34:119-125, 1991.
26. Seghieri G, Yin W, Boni C, Danna G, Anichini R, Bartolomei G, Ferrannini R: Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients. Diabetic Med 9:732-738, 1992.
27. Uehara M, Kishikawa H, Isami S, Kisanuki K, Ohkubo Y, Miyamura N, Miyata T, Yano T, Shichiri M: Effect on insulin sensitivity of angiotensin converting enzyme inhibitors without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans. Diabetologia 37:300-307, 1994.
28. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 24:67-73, 1994.
29. Fliser D, Arnold U, Kohl B, Hartung R, Ritz E: Angiotensin II enhances insulin sensitivity in healthy volunteers under euglycemic conditions. J Hypertens 11:983-988, 1993.
30. Buchanan TA, Thawani H, Kades W, Modrall JG, Weaver FA, Laurel C, Poppiti R, Xiang A, Hsueh W: Angiotensin II increases glucose utilization during acute hyperinsulinaemia via a hemodynamic mechanism. J Clin Invest 92:720-726, 1993.
31. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y, Kurumatani H, Kobayashi F, Kanmatsuse K, Kajiwara N: Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 23:450-455, 1994.
32. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting enzyme inhibition in diabetic nephropathy. N Engl J Med 329:1456-1462, 1993.
33. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane MF: Effects of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138, 1993.
34. Mathiesen ER, Hommel E, Giese J, Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87, 1991.
35. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P: Presentation of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 297:1092-1095, 1988.
36. Viberti G, Morgensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271:275-279, 1994.
37. O'Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH: Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 7:327-332, 1993.
38. Daholf B, Herlitz H, Aurell M, Hansson L: Reversal of cardiovascular structural changes when treating essential hypertension. Am. J Hypertens 5:900-911, 1992.
39. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH, Neaton JD, Stamler J: Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 91:698-706, 1995.
40. Yudkin JS: How can we best prolong life? The benefits of coronary risk factor reduction in diabetic and non-diabetic subjects. BMJ 306:1313-1318, 1993.